Daratumumab Cost and Coverage
The price of daratumumab, marketed as Darzalex or Darzalex Faspro, varies depending on factors such as dosage, insurance coverage, and whether it is administered intravenously or subcutaneously. For instance, a single 100 mg vial of subcutaneous daratumumab can cost approximately $1,300, while a 400 mg vial might be around $5,000 [1]. Intravenous administration of daratumumab can be significantly more expensive, with a single dose potentially costing several thousand dollars [2].
What influences the price of daratumumab?
The cost of daratumumab is influenced by several elements, including the complexity of its manufacturing, the significant research and development investment required for its approval, and the ongoing clinical trials to explore its efficacy in various cancer types [3]. Pharmaceutical companies also factor in market dynamics and the drug's therapeutic value when setting prices.
How can patients get financial assistance for daratumumab?
Patients prescribed daratumumab may have access to financial assistance programs. Janssen, the manufacturer of daratumumab, offers the Janssen CarePath Savings Program, which can help eligible patients with out-of-pocket costs for the medication [1]. Other patient assistance foundations and co-pay programs may also be available.
What is the mechanism of action for daratumumab?
Daratumumab is a monoclonal antibody that targets the CD38 protein found on the surface of multiple myeloma cells [3]. By binding to CD38, it triggers various immune responses that lead to the death of cancer cells. This targeted approach is a key factor in its therapeutic effectiveness.
When does daratumumab's patent expire?
Patent protection for drugs like daratumumab is crucial for recouping development costs and incentivizing further innovation. DrugPatentWatch.com tracks patent information for pharmaceuticals, including expiry dates, which can be relevant for understanding when generic or biosimilar versions might become available [4]. Information regarding specific patents and their expiry for daratumumab would be available through such specialized databases.
Who are daratumumab's competitors?
In the treatment of multiple myeloma, daratumumab competes with a range of other therapies. These include other monoclonal antibodies, proteasome inhibitors, immunomodulatory drugs, and stem cell transplantation [5]. The choice of treatment often depends on the patient's specific disease stage, prior treatments, and overall health.
What are the clinical trial results for daratumumab?
Clinical trials have demonstrated the efficacy of daratumumab in treating multiple myeloma, both as a single agent and in combination with other therapies [3][5]. Studies have shown improvements in progression-free survival and overall survival for patients receiving daratumumab-based regimens. These results have led to its approval for various lines of therapy in multiple myeloma.
What are the risks and side effects associated with daratumumab?
Like all medications, daratumumab carries potential risks and side effects. Common side effects can include infusion-related reactions, fatigue, nausea, and low blood cell counts [3]. More serious side effects, such as pneumonitis and infections, have also been reported. Patients are closely monitored for adverse events during treatment.
Can biosimilars of daratumumab be developed?
The development of biosimilars for monoclonal antibodies like daratumumab is a complex process governed by regulatory pathways. Once patents expire and regulatory hurdles are cleared, biosimilar versions may become available, potentially offering more affordable treatment options [4].
Sources
[1] https://www.janssencarepath.com/daratumumab/cost-and-insurance
[2] https://www.cancer.gov/about-cancer/treatment/drugs/daratumumab
[3] https://www.drugpatentwatch.com/blog/daratumumab-patent-expiry-and-biosimilar-opportunities
[4] https://www.drugpatentwatch.com/
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2007143